Somewhat Favorable News Coverage Somewhat Unlikely to Affect Intra-Cellular Therapies (ITCI) Stock Price
Headlines about Intra-Cellular Therapies (NASDAQ:ITCI) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intra-Cellular Therapies earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.1368788705048 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- Chairman, President & CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Mates Sharon, sells 6,604 shares worth $115,438 (empowerednews.net)
- Intra-Cellular Therapies Inc. (ITCI) Chairman Sharon Mates Sells 6,604 Shares (americanbankingnews.com)
- Kimberly E. Vanover Sells 772 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock (americanbankingnews.com)
- Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. – ITCI – Business Wire (press release) (businesswire.com)
ITCI has been the topic of several recent analyst reports. Zacks Investment Research lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Friday. BidaskClub raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. ValuEngine lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 27th. Canaccord Genuity initiated coverage on Intra-Cellular Therapies in a research report on Friday, December 15th. They set a “buy” rating and a $31.00 price target on the stock. Finally, SunTrust Banks raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $25.56.
Intra-Cellular Therapies (NASDAQ:ITCI) opened at $18.40 on Friday. The firm has a market capitalization of $1,000.00, a price-to-earnings ratio of -8.40 and a beta of 0.72. Intra-Cellular Therapies has a 52-week low of $7.85 and a 52-week high of $22.67.
Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.06 million. Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. Intra-Cellular Therapies’s quarterly revenue was up 675.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.70) earnings per share. equities research analysts anticipate that Intra-Cellular Therapies will post -2.13 EPS for the current fiscal year.
In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 3,192 shares of the business’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $15.67, for a total value of $50,018.64. Following the transaction, the chief financial officer now owns 68,686 shares in the company, valued at $1,076,309.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Sharon Mates sold 6,604 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $17.48, for a total value of $115,437.92. Following the completion of the transaction, the chairman now owns 1,088,707 shares in the company, valued at approximately $19,030,598.36. The disclosure for this sale can be found here. Insiders have sold 49,410 shares of company stock worth $802,481 over the last three months. 21.00% of the stock is owned by insiders.
WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2018/01/12/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-intra-cellular-therapies-itci-stock-price.html.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.